438 related articles for article (PubMed ID: 25486961)
1. Asymptomatic monoclonal gammopathies.
Bories C; Jagannath S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S78-86. PubMed ID: 25486961
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
3. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
6. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG; Laubach J; Mitsiades CS; Schlossman RL; Ghobrial IM; Munshi NC; Anderson KC
Oncology (Williston Park); 2011 Jun; 25(7):594, 596. PubMed ID: 21888257
[No Abstract] [Full Text] [Related]
7. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
9. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
10. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
11. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
13. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
14. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
16. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
18. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
19. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
